Input: Article: During the remainder of his reign, John focused on trying to retake Normandy. The available evidence suggests that John did not regard the loss of the Duchy as a permanent shift in Capetian power. Strategically, John faced several challenges: England itself had to be secured against possible French invasion, the sea-routes to Bordeaux needed to be secured following the loss of the land route to Aquitaine, and his remaining possessions in Aquitaine needed to be secured following the death of his mother, Eleanor, in April 1204. John's preferred plan was to use Poitou as a base of operations, advance up the Loire valley to threaten Paris, pin down the French forces and break Philip's internal lines of communication before landing a maritime force in the Duchy itself. Ideally, this plan would benefit from the opening of a second front on Philip's eastern frontiers with Flanders and Boulogne – effectively a re-creation of Richard's old strategy of applying pressure from Germany. All of this would require a great deal of money and soldiers.

Now answer this question: John did not regard the loss of Duchy as a permanent shift in what?

Output: Capetian power

Input: Article: Others have pointed out that there were not enough of these loans made to cause a crisis of this magnitude. In an article in Portfolio Magazine, Michael Lewis spoke with one trader who noted that "There weren’t enough Americans with [bad] credit taking out [bad loans] to satisfy investors' appetite for the end product." Essentially, investment banks and hedge funds used financial innovation to enable large wagers to be made, far beyond the actual value of the underlying mortgage loans, using derivatives called credit default swaps, collateralized debt obligations and synthetic CDOs.

Now answer this question: What financial innovation allows investment banks and hedge banks to make large wagers?

Output: derivatives

Input: Article: In the UK, the Medicines and Healthcare Products Regulatory Agency approves drugs for use, though the evaluation is done by the European Medicines Agency, an agency of the European Union based in London. Normally an approval in the UK and other European countries comes later than one in the USA. Then it is the National Institute for Health and Care Excellence (NICE), for England and Wales, who decides if and how the National Health Service (NHS) will allow (in the sense of paying for) their use. The British National Formulary is the core guide for pharmacists and clinicians.

Now answer this question: What is the name of the core guide for pharmacists and clinicians?

Output:
British National Formulary